ASCO Abstract #
Tepotinib (c-Met kinase inhibitor): 9082, 9016; M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566; M2698 (dual p70S6k/Akt inhibitor): 2584; M6620 (ATR inhibitor): 2549; M3814 (DNA-PK):2518
- Data from an ongoing Phase II tepotinib study show anti-tumor clinical activity in patients with advanced non-small cell lung cancer harboring MET exon 14 skipping mutations
- Patients with advanced lung cancer harboring MET exon 14 mutations currently have a poor prognosis and limited treatment options
- Safety data are consistent with data previously reported, with no new safety signals identified
DARMSTADT, Germany I June 3, 2018 I Merck KGaA, Darmstadt, Germany, a leading science and technology company which operates its healthcare business in the U.S. and Canada as EMD Serono, today announced that the investigational, targeted therapy tepotinib[*] has shown clinical activity in an ongoing Phase II study of patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. Data from the VISION trial will be presented during the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting in Chicago, June 1-5, 2018.
“Patients living with advanced non-small cell lung cancer harboring MET exon 14 skipping mutations have limited treatment options available to them and typically face poor clinical outcomes,” said investigator Enriqueta Felip, M.D., Medical Oncologist, Vall d’Hebron Institute of Oncology (VHIO). “More than half of the patients in the Phase II VISION study had an investigator-assessed confirmed response, demonstrating the potential of tepotinib and the need to further evaluate this precision medicine option.”
Initial data from the Phase II VISION study of tepotinib in patients living with advanced NSCLC harboring MET exon 14 skipping mutations will be presented today at ASCO during the “Lung Cancer-Non-Small Cell Metastatic” poster discussion session, 11:30 a.m. – 12:45 p.m. CDT. Treatment with tepotinib led to a confirmed complete response (CR) or confirmed partial response (PR) in 53.6% (15/28) and stable disease (SD) in 17.9% (5/28) of patients based on investigator assessment. Based on independent assessment of updated data from 28 patients (patients with at least 2 post-baseline assessments or who discontinued for any reason), 42.9% (12/28) had a PR and 21.4% (6/28) had SD.
In this ongoing study, the safety data are consistent with that observed in previous studies; no new safety signals have been identified to date. A total of 26 out of 38 patients with data available experienced treatment-related adverse events (TRAEs), most commonly Grade 1/2 peripheral edema (13 patients) and diarrhea (10 patients). Seven patients reported Grade 3 TRAEs, including asymptomatic amylase increase (2 patients) and one instance each of: asthenia, generalized edema, aspartate aminotransferase increase, gamma-glutamyl transferase increase, lipase increase, hyperkalemia, dizziness and pneumonia. Four patients experienced serious TRAEs, with one instance of pneumonia, generalized edema, asthenia and dizziness, and interstitial lung disease. The VISION study is continuing to enroll patients harboring MET exon 14 skipping mutations from Europe, United States and Japan.
“These data support our plans to continue with the clinical development of tepotinib in this particularly aggressive, advanced lung cancer. Patients with this form of non-small cell lung cancer currently have a poor prognosis and limited treatment options,” said Luciano Rossetti, M.D., Executive Vice President, Global Head of Research & Development at the biopharma business of Merck KGaA, Darmstadt, Germany. “Tepotinib is an important late-stage investigational therapy and a key part of our strategic focus on innovative precision medicines.”
Tepotinib, discovered in-house at Merck KGaA, Darmstadt, Germany, is an investigational inhibitor of the c-Met receptor tyrosine kinase. Alterations of the c-Met signaling pathway are found in various cancer types and correlate with aggressive tumor behavior and poor clinical prognosis. Tepotinib has been designed with the potential to improve outcomes in aggressive tumors that have a poor prognosis and harbor these specific mutations. In March, the Japanese Ministry of Health, Labour and Welfare granted SAKIGAKE ‘fast-track’ designation to tepotinib in patients with NSCLC harboring MET exon 14 skipping mutations.
SOURCE: Merck KGaA
Post Views: 93
ASCO Abstract #
Tepotinib (c-Met kinase inhibitor): 9082, 9016; M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566; M2698 (dual p70S6k/Akt inhibitor): 2584; M6620 (ATR inhibitor): 2549; M3814 (DNA-PK):2518
- Data from an ongoing Phase II tepotinib study show anti-tumor clinical activity in patients with advanced non-small cell lung cancer harboring MET exon 14 skipping mutations
- Patients with advanced lung cancer harboring MET exon 14 mutations currently have a poor prognosis and limited treatment options
- Safety data are consistent with data previously reported, with no new safety signals identified
DARMSTADT, Germany I June 3, 2018 I Merck KGaA, Darmstadt, Germany, a leading science and technology company which operates its healthcare business in the U.S. and Canada as EMD Serono, today announced that the investigational, targeted therapy tepotinib[*] has shown clinical activity in an ongoing Phase II study of patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. Data from the VISION trial will be presented during the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting in Chicago, June 1-5, 2018.
“Patients living with advanced non-small cell lung cancer harboring MET exon 14 skipping mutations have limited treatment options available to them and typically face poor clinical outcomes,” said investigator Enriqueta Felip, M.D., Medical Oncologist, Vall d’Hebron Institute of Oncology (VHIO). “More than half of the patients in the Phase II VISION study had an investigator-assessed confirmed response, demonstrating the potential of tepotinib and the need to further evaluate this precision medicine option.”
Initial data from the Phase II VISION study of tepotinib in patients living with advanced NSCLC harboring MET exon 14 skipping mutations will be presented today at ASCO during the “Lung Cancer-Non-Small Cell Metastatic” poster discussion session, 11:30 a.m. – 12:45 p.m. CDT. Treatment with tepotinib led to a confirmed complete response (CR) or confirmed partial response (PR) in 53.6% (15/28) and stable disease (SD) in 17.9% (5/28) of patients based on investigator assessment. Based on independent assessment of updated data from 28 patients (patients with at least 2 post-baseline assessments or who discontinued for any reason), 42.9% (12/28) had a PR and 21.4% (6/28) had SD.
In this ongoing study, the safety data are consistent with that observed in previous studies; no new safety signals have been identified to date. A total of 26 out of 38 patients with data available experienced treatment-related adverse events (TRAEs), most commonly Grade 1/2 peripheral edema (13 patients) and diarrhea (10 patients). Seven patients reported Grade 3 TRAEs, including asymptomatic amylase increase (2 patients) and one instance each of: asthenia, generalized edema, aspartate aminotransferase increase, gamma-glutamyl transferase increase, lipase increase, hyperkalemia, dizziness and pneumonia. Four patients experienced serious TRAEs, with one instance of pneumonia, generalized edema, asthenia and dizziness, and interstitial lung disease. The VISION study is continuing to enroll patients harboring MET exon 14 skipping mutations from Europe, United States and Japan.
“These data support our plans to continue with the clinical development of tepotinib in this particularly aggressive, advanced lung cancer. Patients with this form of non-small cell lung cancer currently have a poor prognosis and limited treatment options,” said Luciano Rossetti, M.D., Executive Vice President, Global Head of Research & Development at the biopharma business of Merck KGaA, Darmstadt, Germany. “Tepotinib is an important late-stage investigational therapy and a key part of our strategic focus on innovative precision medicines.”
Tepotinib, discovered in-house at Merck KGaA, Darmstadt, Germany, is an investigational inhibitor of the c-Met receptor tyrosine kinase. Alterations of the c-Met signaling pathway are found in various cancer types and correlate with aggressive tumor behavior and poor clinical prognosis. Tepotinib has been designed with the potential to improve outcomes in aggressive tumors that have a poor prognosis and harbor these specific mutations. In March, the Japanese Ministry of Health, Labour and Welfare granted SAKIGAKE ‘fast-track’ designation to tepotinib in patients with NSCLC harboring MET exon 14 skipping mutations.
SOURCE: Merck KGaA
Post Views: 93
